

Shock or no shock – a question of philosophy or should intraoperative implantable cardioverter defibrillator testing be recommended?†

Andreas Keyser^{a,*}, Michael K. Hilker^a, Sebastian Schmidt^a, Christian von Bary^b, Wolfgang Zink^c, Michael Ried^a, Christof Schmid^a and Claudius Diez^a

^a Department of Cardiothoracic Surgery, University Medical Center, Regensburg, Germany

^b Department of Cardiology, University Medical Center, Regensburg, Germany

^c Department of Anesthesiology, University Medical Center, Regensburg, Germany

* Corresponding author. Department of Cardiothoracic Surgery, University Medical Center, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. Tel: +49-941-9449801; fax: +49-941-9449802; e-mail: andreas-t-keyser@gmx.net (A. Keyser).

Received 21 June 2012; received in revised form 30 September 2012; accepted 22 October 2012

Abstract

OBJECTIVES: Implantation of implantable cardioverter defibrillators (ICDs) in patients with a high risk for life-threatening ventricular arrhythmias is a standard therapy. The development of new ICD leads, shock algorithms, high-energy defibrillators and rapid energy supply has improved the devices. Nevertheless, the discussion regarding 'shock or no shock' to test the system intraoperatively has not silenced yet.

METHODS: In this study, all 718 patients (60.0 ± 14.2 years old, 570 male) who were treated with a first ICD at our institution since 2005 were analysed. The indication for implantation was primarily prophylactic in 511 patients (71.3%). Underlying diseases included ischaemic cardiomyopathy (358 patients, 50%), dilated cardiomyopathy (270 patients, 37.7%) and others (12.3%). Mean ejection fraction was 27.4 ± 11.8%. Intraoperative ventricular fibrillation was induced with a T-wave shock or burst stimulation. The primary end-point was failing the initial intraoperative testing.

RESULTS: During the initial testing, 28 patients (3.9%) had a defibrillation threshold (DFT) >21 J. The mean age of these patients was 51 ± 14 years, ranging from 22 to 71 years, 20 were male, and the ejection fraction was 23.8 ± 11.8%. The indication for ICD implantation was prophylactic in 13 patients. Twenty-one of the 28 patients suffered from dilated cardiomyopathy, whereas seven patients had ischaemic cardiomyopathy. Twenty-four ICDs were implanted on the left side and four on the right side. None of the patients had been treated with amiodarone at the time of implantation. All patients achieved a sufficient DFT ≤21 J by changing the ICD leads, device repositioning and/or optimizing the shock configuration.

CONCLUSIONS: The standard of care intraoperative ICD testing remains necessary.

Keywords: Implantable cardioverter defibrillator • Intraoperative test

INTRODUCTION

Since introduction of implantable cardioverter defibrillators (ICDs) in the early 1980s by Mirowski *et al.* [1], multiple studies have extended the indication for placement of ICDs in patients with a high risk for life-threatening ventricular arrhythmias, as has been summarized in the guidelines for the treatment of acute and chronic heart failure [2]. Meanwhile, the implantation is a standard therapeutic method, which has been considerably improved over time by the development of new ICD leads, shock algorithms, high-energy defibrillators and rapid energy supply. The latest development in ICD capacitors was introduced 2005.

Yet, the discussion regarding 'to shock or not to shock' in order to test the system intraoperatively remains controversial. Supporting

arguments for testing of the implanted system vary from quality control regarding lead reliability, appropriate detection of ventricular tachycardia and/or ventricular fibrillation (VF) and sufficient device functioning up to patient's safety [3, 4]. There are also multiple arguments against intraoperative testing, ranging from the avoidance of adverse events during the procedure to the clinical outcome through statistical analysis [5, 6]. Hence, review of the current literature does not answer the question of whether it can be recommended to refrain from testing a newly implanted ICD.

PATIENTS AND METHODS

Since 1996, our institution has implanted 1512 ICDs. To avoid bias of the study, all patients requiring ICD therapy participated. Within the study period from July 2005 until June 2011, 718 patients received their first ICD (one-, two or three-chamber ICD).

†Presented at the 41st Annual Meeting of the German Society for Cardiovascular and Thoracic Surgery, Freiburg, Germany, 12–15 February 2012.

Exclusion criteria

Two patients had to be excluded from the study due to left ventricular thrombi. Of the remaining 716 patients, the primary endpoint of the study was patients failing the initial intraoperative testing of the system implanted.

Surgery

All patients underwent general anaesthesia for the operative procedure, which was performed by a cardiac surgeon. Leads were placed via a cephalic vein and/or subclavian vein. Only dual-coil defibrillation leads were implanted. Left ventricular leads were positioned either endocardially or epicardially (two patients received epicardial defibrillator patches owing to occlusion of both of their subclavian and jugular veins). All devices were implanted subpectorally.

The devices were implanted on the left side in 680 (96%) of the patients; only for exceptional reasons was the implantation performed on the right side (e.g. occluded left subclavian vein or pacemaker on the right side).

All implanted systems were high-energy ICDs with maximal deliverable shock energy ≥ 31 J (Biotronic, Boston Scientific, Medtronic and St Jude Medical). An adequate ventricular sensing of >6 mV and a pacing threshold of <1 V was attempted in all cases.

Testing

According to the protocol, VF was induced by T-wave shock or, if the T-wave shock failed to induce VF, by 50 Hz pacing. The test shock was programmed at 21 J. In the event of ongoing VF, external defibrillation was then used to terminate VF. If successful termination of VF could not be achieved with internal electrodes, the defibrillation lead was repositioned and testing repeated. Programming reversed polarity, use of a single coil and repositioning of the device caudo-medially or laterally were carried out as further options if the system still failed to terminate VF, with each step being tested again to reach a defibrillation threshold (DFT) ≤ 21 J.

Statistical analysis

Statistical analysis was performed with Stata 10.1 SE for Windows (StataCorp., College Station, TX, USA). Continuous data were first tested for normality with the Shapiro-Wilk test and graphically with quantile-quantile plots. If normally distributed, these data are presented as means \pm SD or, if non-normally distributed, as medians with the interquartile range. Dichotomous data are expressed as numbers and percentages. Univariate comparisons were tested with Fisher's exact test or the chi-squared test for categorical variables. Student's unpaired *t*-test was used for continuous normally distributed variables or the Mann-Whitney *U*-test for non-normally distributed data. The tests were performed two-sided, and a *P*-value of <0.05 was considered to be statistically significant.

RESULTS

In the investigated group of 716 patients operated upon within the last 6 years, no major adverse events, including death, stroke

and cardiopulmonary depression, occurred during implantation and testing.

In 28 patients (3.8%), a DFT >21 J was noted with the initial shock configuration, which necessitated correction of the defibrillation system (study group). The mean age of these patients was 51 ± 14 years, ranging from 22 to 71 years (study group vs all patients, $P < 0.0009$). There were 20 male and eight female patients. The ejection fraction was $23.8 \pm 11.8\%$. Twenty-four ICDs were implanted on the left and four on the right side. The failure rate of implanted devices on the right appeared to be significantly higher than that of devices being implanted on the left ($P = 0.02$). Demographic data are summarized in Table 1.

In 13 patients, the indication for ICD implantation was prophylactic according to the Multicenter Automatic Defibrillator Implantation Trial II (MADIT) criteria. The underlying diagnosis of dilated cardiomyopathy was found in 20 of the 28 patients, whereas the remaining eight patients suffered from ischaemic cardiomyopathy, i.e. there were significantly more cases of dilated cardiomyopathy in the study group ($P = 0.001$). Underlying diseases of the patients and indications for device implantation are summarized in Table 2.

Thirteen patients received a single chamber ventricular system; two of them presented with chronic atrial fibrillation. Twelve patients were provided with a dual chamber system; four of them suffered from sick sinus syndrome, four from

Table 1: Demographic data

Patients	Successful test (n = 688)	Failing initial shock (n = 28)	Significance
Age (years)			
Mean	60 \pm 14	51 \pm 14	$P = 0.0009$
Median	63	49	
Gender			
Male	550 (80%)	20 (71%)	$P = 0.336$
Female	138 (20%)	8 (29%)	
Ejection fraction (%)	27.4 \pm 11.8	23.9 \pm 11.8	$P = 0.124$
Implantation site			
Left	663 (96%)	24 (86%)	$P = 0.023$
Right	25 (4%)	4 (14%)	

Table 2: Underlying diseases and implantation indication

Patients	Successful test (n = 688)	Failing initial shock (n = 28)	Significance
DCM	250 (36.4%)	20 (71.5%)	$P = 0.001$
ICM	350 (50.9%)	8 (28.5%)	
Brugada	29 (4.2%)	0	$P = 0.83$
Long QT	16 (2.3%)	0	
HOCM	20 (2.8%)	0	
Other	23 (3.4%)	0	
Primary	490 (71.2%)	21 (75%)	
Secondary	198 (28.8%)	7 (25%)	

DCM: dilated cardiomyopathy; HOCM: hypertrophic obstructive cardiomyopathy; ICM: ischaemic cardiomyopathy; n.s.: not significant; other: amyloidosis, fibrosis; primary: primary prevention indication; secondary: secondary prevention indication.

intermittent atrial fibrillation, and two patients each from atrioventricular block II type Mobitz and atrioventricular block III, respectively. Three patients were treated with cardiac resynchronization therapy (CRT-D) due to additional left bundle branch block (Table 3). None of the patients received amiodarone at the time of implantation.

All 28 patients successfully reached a DFT ≤ 21 J and a safety margin of >10 J by changing the position of the ICD lead, replacing the device and/or optimizing the shock configuration (Table 4).

DISCUSSION

The discussion about whether or not to test a newly implanted ICD system has witnessed a renaissance during the last years,

owing to improvements in ICD technology, including rapid onset and high energy supply. Yet, there is no evidence that even the highest energy supply with modern ICD devices permits the abandoning of intraoperative testing [4].

The prerequisite for an appropriate ICD function is the determination of the DFT or a safety margin of 10 J [7]. A further advantage of the testing procedure is the detection of ventricular arrhythmias (ventricular tachycardia and/or VF), as well as the analysis of lead function and system integrity to rule out the rare case of device failure [4]. Previous studies demonstrated an alarming rate of insufficient security in ICD patients when intraoperative testing was omitted [8]. In a study of 440 consecutive patients, Alter *et al.* reported inappropriate shocks in 12% of patients [9]. A first 20 J shock efficacy of 83%, i.e. a failure rate of 17%, was shown by Blatt *et al.* [5]. Christ *et al.* stated a shock failure rate of only 3%; however, with intraoperative corrections of the implanted system in 17% of their patients [10]. Only one study demonstrated no inappropriate shocks in their group of 42 patients assigned to intraoperative DFT testing, treated from 1995 to 1996. One may assume that the number of patients in that study was too small for a valid conclusion [6]. In our study, which was designed to include all consecutive patients (all comers), we found a first shock failure rate of 3.9%. It is noteworthy that 14% of these patients had their device implanted on the right side, which was significantly more than in the patient group with successful testing.

The probability of defibrillation is a statistical value in accordance with a dose-response curve. Testing of an ICD indicates a statistical probability of successful therapy. Multiple testing may

Table 3: Devices

Patients	Successful test (n = 688)	Failing initial shock (n = 28)	Significance
VVI	420 (61%)	13 (46%)	P = 0.16
DDD	179 (26%)	12 (43%)	P = 0.08
CRT	89 (13%)	3 (11%)	P = 1.00

CRT: resynchronization ICD; DDD: two-chamber ICD; VVI: one-chamber ICD.

Table 4: Intraoperative numbers and types of corrections and numbers of shocks applied intraoperatively

Age	Gender	ICD site	Lead reposition	Dual → single coil	Configuration	Device reposition	Total number of shocks
41	F	Left	1	1			5 (2)
53	M	Right	1	1			3 (1)
64	M	Left	1	1			5 (1)
60	M	Left	1				3 (1)
68	F	Left	2				5 (2)
49	M	Left	1				4 (2)
61	M	Left	1				3 (1)
22	M	Left	1	1	1	1	7 (3)
44	M	Left	1	1	1		5 (2)
54	M	Right	1	1			3 (1)
67	F	Left	1				3 (1)
38	M	Left	1				3 (1)
34	M	Left	3	1	1		6 (3)
70	M	Right	1				3 (1)
48	F	Left	1				3 (1)
49	F	Left	4	1	1	2	15 (7)
64	F	Right	2	1			7 (3)
43	M	Left	1	1			5 (2)
71	M	Left	1				3 (1)
50	M	Left	1				3 (1)
63	F	Left	1				3 (1)
47	M	Left	1	1	1		5 (2)
66	M	Left	2	1	2*	2	12 (6)
23	M	Left	1				3 (1)
24	F	Left	1	1			3 (1)
44	F	Left	2				5 (2)
48	M	Left	1				4 (3)
67	M	Left	1				3 (1)

The number of external defibrillations is given in parentheses. *Configuration changed to single coil and back to dual coil. Configuration indicates reversed polarity.

strain the probability of appropriate therapy, but an absolute security, i.e. a successful therapy in all cases, will remain unachievable. As the energy supply in the new generation of ICDs is rather rapid, myocardial ischaemia nowadays seems unlikely to be the reason for test failure. Shuger *et al.* demonstrated that prolonged procedure times and larger left ventricular diastolic diameters (>61 mm) were predictors of testing failure [11]. In our analysis, we also found a statistically significant shift towards dilated cardiomyopathy patients with regard to failed initial intraoperative testing ($P = 0.001$). Given that multiple testing, with repeat induction and consecutive cardioversions/defibrillations, for exact determination of the DFT also significantly burdens the patient, its usefulness can be questioned [12]. In 2002, the Low Energy Safety Study aimed at very low energy margins, but nearly half of their patients did not reach the safety margin of 10 J [13]. Thus, the aim of testing the safety margin primarily lowered the probability of retesting, as in our study. This fact, together with the aforementioned abandoned multiple testing for DFT, has been used as a strong argument against testing [14].

It is questionable whether there are clinical conditions in favour or against DFT testing and safety margin assessment.

Ventricular fibrillation can be induced by a T-wave shock or by burst stimulation, both of which lead to different characteristics of VF [15]. Moreover, induced and spontaneous episodes of VF are different, as are sustained and self-terminating episodes [16, 17]. Viskin and Rosse proposed that the decision concerning whether to test or not should be based on the characteristics of VF [14]. Given that arrhythmia may vary and that any ventricular arrhythmia should be terminated by adequate defibrillation, we do not recommend their suggestion [18].

Strickberger and Klein assumed an efficacy of about 5% when additional modifications of the implanted system are necessary to achieve an adequate DFT [3]. However, our system revisions after failed initial testing, which included lead repositioning, device relocation and alteration of the device configuration, were uniformly successful.

Atary *et al.* recommended refraining from intraoperative testing as a consequence of an adequate right ventricular threshold [19]. However, all our patients demonstrated adequate ventricular sensing of >6 mV and a pacing threshold of <1 V prior to testing. Thus, our data do not prove the hypothesis that the right ventricular stimulation threshold alone provides sufficient evidence for appropriate device function.

The main arguments against intraoperative testing are major adverse events, such as intractable VF, haemodynamic deterioration, neurological impairment and death [9, 20]. In a Canadian study population of 19 067 patients, death in association with defibrillator testing had a prevalence of 0.016%. Strokes have been observed in 0.026 and 0.5% of patients, respectively [9, 20]. In contrast, Healey *et al.* found no differences with regard to perioperative complications in patients having been tested or not [21]. In our total collective of 1512 patients treated from 1996 to date, we observed no strokes and no deaths related to intraoperative testing. We think that an adequate surgical implantation time, as well as strict adherence to the implantation protocol during surgery, especially concerning therapeutic procedures in the event of intractable VF, enhances the safety of a patient.

It has also been discussed that the majority of ICDs never treat ventricular arrhythmias and therefore do not need to be tested [14]. However, given that a significant survival benefit of

primary ICD therapy has been shown [22, 23], appropriate testing seems important.

Three of the 28 patients who failed the initial intraoperative test had pacemaker leads implanted prior to the ICD implantation. These patients had their ICD implanted on the right side ($P = 0.02$). The reason for the initial testing failure in these three patients appears to be manifold. Devices implanted on the right side theoretically may not have an optimal shock vector and therefore might be prone to failure. None of the multiple studies has analysed the operating procedures, intraoperative testing and the outcome of patients being supplied with an ICD in the right pectoral region.

Amiodarone has been identified as a positive predictor for a DFT >25 J [8, 24]. Napp *et al.* especially recommended testing in young patients treated with amiodarone, but questioned the need for general intraoperative testing. None of our 28 patients was treated with amiodarone at the time of ICD implantation, but like in Napp's group, our patients who failed the initial intraoperative test were significantly younger on average [24].

CONCLUSION

The development of new ICD leads, shock algorithms, high-energy defibrillators and rapid energy supply has improved ICDs. Testing of ICDs is a safe and efficient procedure. Alterations of the implanted system, such as lead repositioning, device relocation and changing the device polarity, are effective means to achieve sufficient sensing and an appropriate safety margin to terminate life-threatening ventricular arrhythmias. The paradigm should not yet shift to elimination of ICD testing. Failure to test the DFT or failure to confirm safety margins is not the answer to improvement of ICDs.

Conflict of interest: none declared.

REFERENCES

- [1] Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF *et al.* Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. *N Engl J Med* 1980; 303:322-4.
- [2] Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA *et al.* ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J* 2008;29:2388-442.
- [3] Strickberger SA, Klein GJ. Is defibrillation testing required for defibrillator implantation? *J Am Coll Cardiol* 2004;44:88-91.
- [4] Ideker RE, Epstein AE, Plump VJ. Should shocks still be administered during implantable cardioverter-defibrillator insertion? *Heart Rhythm* 2005;2:462-3.
- [5] Blatt JA, Poole JE, Johnson GW, Callans DJ, Raitt MH, Reddy RK *et al.*; SCD-HeFT Investigators. No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). *J Am Coll Cardiol* 2008;52:551-6.
- [6] Calvi V, Dugo D, Capodanno D, Arancio R, Di Grazia A, Liotta C *et al.* Intraoperative defibrillation threshold testing during implantable cardioverter-defibrillator insertion: do we really need it? *Am Heart J* 2010;159:98-102.
- [7] Day JD, Doshi RN, Belott P, Birgersdotter-Green U, Behboodikhah M, Ott P *et al.* Inductionless or limited shock testing is possible in most

patients with implantable cardioverter-defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (arrhythmia single shock defibrillation threshold testing versus upper limit of vulnerability: Risk reduction evaluation with implantable cardioverter-defibrillator implantations). *Circulation* 2007;115:2382-9.

- [8] Higgins S, Mann D, Calkins H, Estes NA, Strickberger SA, Breiter D *et al.* One conversion of ventricular fibrillation is adequate for implantable cardioverter-defibrillator implant: an analysis from the Low Energy Safety Study (LESS). *Heart Rhythm* 2005;2:117-22.
- [9] Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. *Pacing Clin Electrophysiol* 2005;28:926-32.
- [10] Christ C, Becker R, Voss F, Kelemen K, Senges-Becker J, Hauck M *et al.* Indications for premissal testing with arrhythmia-induction in patients receiving an implantable cardioverter defibrillator. *Clin Res Cardiol* 2007;96:613-20.
- [11] Schuger C, Ellenbogen K, Faddis M, Knight BP, Yong P, Sample R. Defibrillation energy requirements in an ICD population receiving cardiac resynchronization therapy. *J Cardiovasc Electrophysiol* 2006;17:247-50.
- [12] Joglar JA, Kessler DJ, Welch PJ, Keffer JH, Jessen ME, Hamdan MH *et al.* Effects of repeated electrical defibrillations on cardiac troponin I levels. *Am J Cardiol* 1999;83:270-72.
- [13] Mann DE, Klein RC, Higgins SL, Freedmann RA, Hahn SJ, Huang ZZ. The Low Energy Safety Study (LESS): rationale, design, patient characteristics, and device utilization. *Am Heart J* 2002;143:199-204.
- [14] Viskin S, Rosse R. The top 10 reasons to avoid defibrillation threshold testing during ICD implantation. *Heart Rhythm* 2008;5:391-3.
- [15] Taneja T, Goldberger J, Johnson D, Kadish A. Is all ventricular fibrillation the same? Influence of mode of induction on characteristics of ventricular fibrillation. *J Cardiovasc Electrophysiol* 2000;11:1355-63.
- [16] Lever NA, Newall EG, Larsen PD. Differences in the characteristics of induced and spontaneous episodes of ventricular fibrillation. *Europace* 2007;9:1054-8.
- [17] Mäkikallio TH, Huikuri HV, Myerburg RJ, Seppänen T, Kloosterman M, Interian A Jr *et al.* Differences in the activation patterns between sustained and self-terminating episodes of human ventricular fibrillation. *Ann Med* 2002;34:130-5.
- [18] Zima E, Gergerly M, Soós P, Gellér LA, Nemes A, Acsády G *et al.* The effect of induction method on defibrillation threshold and ventricular fibrillation cycle length. *J Cardiovasc Electrophysiol* 2006;17:377-81.
- [19] Atary JZ, Borleffs CJ, van der Bom JG, Trines SA, Bootsma M, Zeppenfeld K *et al.* Right ventricular stimulation threshold at ICD implant predicts device therapy in primary prevention patients with ischaemic heart disease. *Europace* 2010;12:1581-8.
- [20] Birnie D, Tung S, Simpson C, Crystal E, Exner D, Ayala Paredes FA *et al.* Complications associated with defibrillation threshold testing: the Canadian experience. *Heart Rhythm* 2008;5:391-3.
- [21] Healey JS, Birnie DH, Lee DS, Krahn AD, Crystal E, Simpson CS *et al.* Defibrillation testing at the time of ICD insertion: an analysis from the Ontario ICD registry. *J Cardiovasc Electrophysiol* 2010;21:1344-8.
- [22] Goldberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S *et al.* Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the multicenter automatic defibrillator implantation trial II. *Circulation* 2010;122:1265-71.
- [23] Parkash R, Sapp JL, Basa M, Doucette S, Thompson K, Gardner M *et al.* Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with significant survival benefit. *Circ Arrhythm Electrophysiol* 2012;5:706-13.
- [24] Napp A, Birkenhauer F, Lee KM, Gemein C, Zink M, Knackstedt C *et al.* ICD-test: is the evaluation of the defibrillation threshold (DFT) still up to date? The ATLANTIS Register. *Eur Heart J* 2010;31:928-9.

eComment. Intraoperative implantable cardioverter defibrillator testing

Authors: Murat Unlu, Sevket Balta, Mustafa Cakar and Sait Demirkol

Department of Cardiology, Beytepe Hospital, Ankara, Turkey

doi:10.1093/icvts/ivs573

© The Author 2013. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

We read the article by Keyser *et al.* with interest [1]. They investigated 718 patients (60.0 ± 14.2 years; male, n = 570) who were treated with a first implantable cardioverter defibrillator (ICD) at their institution analysed since 2005.

Pacemaker and ICD implantation is often regarded as a simple and easy procedure, ideal for beginners in cardiac and general surgery. Pacemaker and ICD implantation has become a routine procedure in modern cardiology, and implantable cardioverter-defibrillators are implanted with increasing frequency. Although fatal complications are relatively rare, they may give rise to malpractice lawsuits against medical personnel [2]. A frequently under-diagnosed complication of pacemaker and implantable cardioverter defibrillator lead implantation is the unintentional advancement of the leads into the systemic circulation. Despite standardized procedures and improvements in the technique of pacemaker implantation, life-threatening complications may still occur. Even in the hands of experienced physicians, pacemaker leads can be misplaced into the systemic circulation during implantation [3]. The most common complications of lead implantation through a coronary vein, however, are diaphragmatic stimulation, coronary sinus dissection, and lead dislodgement [4]. We think that detailed and careful consideration should be made during the process of installation of the device, not only to determine the appropriate defibrillation threshold, but also to determine the proper localization of ICD leads and mechanical complications. Accordingly, we agree with the authors that the testing of ICDs is a safe and efficient procedure.

Conflict of interest: none declared

References

- [1] Keyser A, Hilker MK, Schmidt S, von Bary C, Zink W, Ried M *et al.* Shock or no shock—a question of philosophy or should intraoperative implantable cardioverter defibrillator testing be recommended? *Interact CardioVasc Thorac Surg* 2013;16:321-6.
- [2] Schulz N, Püschel K, Turk EE. Fatal complications of pacemaker and implantable cardioverter-defibrillator implantation: medical malpractice? *Interact CardioVasc Thorac Surg* 2009;8:444-8.
- [3] Alozie A, Westphal B, Yerebakan C, Steinhoff G. Transient ischaemic attack due to the lead of an implantable defibrillator in the left heart. *Interact CardioVasc Thorac Surg* 2012;14:128-30.
- [4] Yoda M, Tanabe H, Kishi M, Suma H. Alternative technique for implanting an epicardial cardioverter defibrillation patch during a tricuspid valve replacement for arrhythmogenic right ventricular cardiomyopathy. *Interact CardioVasc Thorac Surg* 2011;12:628-30.

eComment. Shock or no shock: individual option for some patients

Authors: Leo Bokeria, Andrey Filatov and Alexey Kovalev

Bakoulev Center for Cardiovascular Surgery Russian Academy of Medical Sciences, Moscow, Russia

doi:10.1093/icvts/ivs578

© The Author 2013. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Although ICD implantation has become a cornerstone in primary and secondary prevention of sudden cardiac death, many problems are still encountered due to tachycardia cycle length, morphology and frequency, as well as different organic heart pathology. Therefore it is necessary to prevent different conditions which may promote high defibrillation thresholds. In this article, the authors tried to determine these specific conditions [1]. Similar studies have also been reported by Lin *et al.* [2] and Vischer *et al.* [3].

All of these studies place patients with low left ventricular ejection fraction and young age in the high risk group. The major risks of DFT testing are related to DFT test-induced ventricular fibrillation and the electric shock itself. Ventricular fibrillation may stop blood flow and cause associated complications, including hypoperfusion of the central nervous system, myocardial ischaemia and electro-mechanical dissociation following defibrillation. Electric shock may cause myocardial damage and dislodgement of thrombi. In addition, a large number of patients undergo the implantation procedure under regional anaesthesia. Patients requiring ICD implantation can be divided into three groups according to indications: 1) chamber devices for primary and secondary prevention without other conduction diseases, 2) chamber devices for patients with conduction system disturbances, and 3) chamber devices for resynchronization. DFT test performance in patients from the first and second groups may be unnecessary: in view of the high risk of sudden cardiac death, shock energy in these patients should be more than 25 J. The DFT test can be performed in patients with structural pathology, especially with dilated and ischaemic cardiomyopathy causing giant chamber size and non-compact myocardium, to avoid high defibrillation threshold by means of changing polarity and defibrillation vector.